Faster-acting insulin aspart (FIAsp) success in Phase III trials compared to NovoRapid (insulin aspart) in Diabetes-Novo Nordisk
Novo Nordisk has announced headline results from the final Phase IIIa trials for faster-acting insulin aspart, ONSET 1 and ONSET 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively . Both trials achieved their primary objectives by demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid with regard to lowering of HbA1c. For people with type 1 diabetes, the HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid when the insulins were given at mealtime. In addition, treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid during meal tests in both trials. In both trials, the previously reported safety and tolerability profiles of faster -acting insulin aspart and NovoRapid were confirmed, and there were no apparent differences between the two treatment groups with respect to adverse events and other safety parameters.
Comment: Novo Nordisk�s FIAsp is the ultra-rapid-acting insulin that follows behind Afrezza (an ultra-rapid-acting inhaled mealtime insulin for people with type 1 and type 2 diabetes) from Sanofi (formerly Mannkind). Afrezza is now approved in both FDA and EU in 2014.
Related news and insights
CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (“MCV4”, trade name: Menhycia), making it the first of its kind to be authorized in China.
Basilea Pharmaceutica Ltd. announced that its license partner, Pfizer Inc. has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis. This is the second approved indication for oral Cresemba in China, after the approval for the treatment of adult patients with invasive mucormycosis, which was received in December 2021.
AbbVie announced the FDA has approved Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.